Study shows erlotinib can improve the survival rate for patients with non-small cell lung cancer.
A new study published in Lancet Oncology has found that the drug Erlotinib (brand name: Tarceva), when administered after a chemotherapy treatment, can improve the survival rate for patients with non-small cell lung cancers (NSCLC).  The drug had previously been used to treat both NSCLC and pancreatic cancer, but this was one of the first trials of the...